Article

Dr. Marcus Wilson Discusses How Comparative Effectiveness Research is Used in the Managed Care Setting

Marcus D. Wilson, PharmD, President, HealthCore, states that there is variability within and between different organizations that utilize comparative effectiveness research.

Marcus D. Wilson, PharmD, President, HealthCore, states that there is variability within and between different organizations that utilize comparative effectiveness research.

Comparative effectiveness research is used to better understand populations impacted by decisions, and is used to customize policy for specific populations.

Related Videos
Dr Gerard Criner
Emma Achola-Kothari, PhD
Dr Margrit Wiesendanger
Dr Emma Achola-Kothani
Marla Black Morgan, MD, Phoebe Neurology Associates
Christine Funke, MD
Toby Maher, MD, PhD, professor of clinical medicine, Keck School of Medicine at USC
Nini Wu, MD, Navista
Fred Locke, MD, Moffitt Cancer Center and Research Institute
Related Content
Adolescent patients were more likely to be most bothered by feelings of anxiety or atopic dermatitis affecting their daily activities. | Image Credit: InfiniteStudio - stock.adobe.com
May 22nd 2025

Patient-Reported Experiences Show Psychological Impact of Atopic Dermatitis on Adolescents

AJMC Contributor
The findings, which add to the limited data on the burden of atopic dermatitis on adolescent and pediatric patients, showed differences in what was most bothersome to the younger group of patients.
Managed Care Cast
May 20th 2025

Mental Health Awareness: Transforming Workplace Support and Engagement

Giuliana Grossi Jim Kinville
Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.
Even among patients with MDS and anemia with a high transfusion burden, 7 of 12 patients who responded experienced responses lasting longer than 6 months. | Image Credit: Eleni - stock.adobe.com
May 22nd 2025

Safety, Efficacy of Luspatercept for MDS Confirmed in Real-World Setting

Rose McNulty
Luspatercept showed real-world efficacy among patients with lower-risk myelodysplastic syndrome (MDS), confirming results seen in clinical trials.
managed care cast logo
May 13th 2025

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Brooke McCormick Larragem Raines, MS
Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com
May 18th 2025

Novel, Noninvasive Skin Cancer Detection Method Shows Promise

Jared Kaltwasser
The tool could make it easier for clinicians to rule out melanoma without the need for excision.
Among patients in the real-world setting, acalabrutinib was associated with reduced risks of AF or flutter and a reduced risk of hypertension. | Image credit: inthasone - stock.adobe.com
May 17th 2025

Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study

AJMC Contributor
The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo